Introduction
============

Hepatitis C Virus is an enveloped positive sense single-stranded RNA virus that infects more than 170 million people (∼2% of the world's population) ([@B5]). A majority of the individuals infected with HCV develop chronic hepatitis and a proportion will develop cirrhosis and liver carcinoma. HCV remains the most common reason for liver transplantation worldwide ([@B5]).

The introduction of highly effective direct acting antivirals (DAA) designed to inhibit the function of specific non-structural (NS) viral proteins critical to viral replication has resulted in high cure rates in most patients, a shortened duration of treatment and is associated with relatively few side effects. However, the use of DAA is limited by the high cost (up to US\$147,000 for 12-week treatment course) ([@B3]; [@B82]). As a consequence, it is estimated that approximately ∼1% of those diagnosed with hepatitis C virus infection are treated annually in Australia ([@B29]), while the global pool of HCV infected persons is increased by 3--4 million new infections each year ([@B46]). Furthermore, the World Health Organization (WHO) estimates that as of 2015 only 20% of those infected with HCV were aware of their diagnosis and only 7.4% of those diagnosed with HCV were placed on treatment worldwide ([@B100]). Consequently, developing a safe, effective and inexpensive HCV vaccine is therefore necessary to control global infection and reduce the financial burden on healthcare systems.

However, the development of an effective HCV vaccine is hindered by several factors including the high genetic variability of the virus genome that gives rise to escape mutants which can evade both cellular and humoral host immune responses. Moreover, currently there are no suitable small animal models available that can mimic HCV infection of humans. Furthermore, humans and chimpanzees who have been previously treated and cured of hepatitis C could be re-infected after re-exposure to the virus ([@B39]; [@B21]). Conversely, there is some optimism that the development of a successful HCV vaccine might be possible because a proportion of infected individuals (15--25%) clear the virus naturally and develop some immunity that is able to reduce the duration of viremia and the viral load in subsequent infections ([@B78]; [@B47]). An understanding of the antiviral immune responses in these individuals and in the chimpanzee model have elucidated key mechanisms thought to contribute to the control of HCV infection. It was demonstrated that the induction and maintenance of strong CD4++ and CD8+ T cell immune responses against various viral epitopes are associated with the resolution of HCV infection ([@B44]; [@B90], [@B89]; [@B102]). It is now thought that a cell-mediated response alone is not sufficient and that the timely induction of cross-neutralizing antibodies (NAbs) is important for protection and in viral clearance ([@B40]; [@B103]; [@B74]).

Licensed viral vaccines such as poliovirus, induce NAbs against viral surface proteins to provide protection. However, despite the development of an efficient system for HCV culture ([@B62]; [@B98]; [@B107]), it is still not feasible to generate a vaccine based on killed or live-attenuated HCV due to the potential dangers associated with the use of such particles ([@B43]). These shortcomings have led to the development of experimental vaccines which include DNA vaccines, recombinant (non-pathogenic) vectors, proteins and virus like particles (VLPs). Despite the many obstacles that impede the development of these vaccines, several studies involving VLP-based vaccine candidates have already generated promising results in preclinical studies ([@B68]; [@B52]; [@B36]; [@B76]; [@B84]; [@B45]; [@B96]; [@B17]; [@B50]; [@B14]). This article will review HCV vaccine strategies based on homologous or heterologous HCV VLPs (**Table [1](#T1){ref-type="table"}**), plasmid DNA and viral vectors encoding HCV-VLPs (**Table [2](#T2){ref-type="table"}**) as well as various expression systems (**Table [3](#T3){ref-type="table"}**) utilized in the production of HCV VLP vaccines.

###### 

Homologous and recombinant Hepatitis C Virus (HCV) virus-like particle vaccines.

  Viral structural components   Expression system   Cells                     Route of administration                       HCV antigen                        Animal studies         Reference
  ----------------------------- ------------------- ------------------------- --------------------------------------------- ---------------------------------- ---------------------- --------------------------------
  HCV-core                      Insect cells        Sf-9                      Intraperitoneal and intramuscular             Core, E1, and E2                   Mice and chimpanzees   [@B10]; [@B60]; [@B68]; [@B36]
                                Mammalian           Huh-7                     Subcutaneous                                  Core, E1, and E2                   Mice                   [@B56]
                                Yeast               *P. pastoris*             Subcutaneous                                  Core, E1 and E2                    Rabbits                
  HBcore                        Bacteria            *E. coli* (GI698 cells)   Subcutaneous                                  Core (98 aa) and NS3 (155 aa)      Mice                   [@B66]
                                                    *E. coli* (K802 cells)    Subcutaneous                                  Core (60 aa) also HBV-S1 (27 aa)   Mice                   [@B88]
  HBsAg                         Mammalian           Huh-7, HEK293T            Subcutaneous                                  E2 HVR-1 (36 aa)                   Mice                   [@B70], [@B71]; [@B97]
                                                    CHO cells                 Subcutaneous                                  E1, E2, and E1E2                   Rabbits                [@B12], [@B13]; [@B14]
  PapMV CP                      Bacteria            *E. coli*                 Subcutaneous                                  E2                                 Mice                   [@B31]
  MLV Gag                       Mammalian           HEK293T                   Subcutaneous, intramuscular and intradermal   E1 and E1E2                        Mice and macaques      [@B32]; [@B45]; [@B50]
                                                                              Intradermal                                   NS3                                Mice                   [@B50]
  TMV CP                        Plant cells         *N. benthamiana*          Intranasal                                    E2 HVR-1 mimotope R9               Mice                   [@B69]
                                                                                                                                                                                      

###### 

Plasmid DNA and viral vectors expressing HCV virus-like particle vaccines.

  Vector        Viral capsid components   Route of administration           HCV antigen        Animal studies   Reference
  ------------- ------------------------- --------------------------------- ------------------ ---------------- ----------------
  rVSV          HCV-core                  Intravenous and intraperitoneal   Core, E1, and E2   Mice             [@B64]
  Plasmid DNA   HCV-core                  Intradermal and intramuscular     Core, E1, and E2   Mice             [@B68]
                MLV Gag                   Intradermal                       E1 and E2          Mice             [@B32]; [@B50]
                                                                            NS3                Mice             [@B50]
                                                                                                                

###### 

Comparison of VLP expression system.

  VLP expression system   Merits                                                                                                                                                                                      Demerits
  ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bacteria                Less expensive; simplicity of expression; fast growth rate; high-level expression; genetic stability; simple process scale-up                                                               Lack mammalian-like PTM; Poor ability on immunogenicity; Presence of host cell-derived contaminants
  Yeast                   Less expensive; high-density fermentation; modification of the expression protein; moderately rapid expression; support most protein folding and PTM                                        High mannose modification; some secretory proteins cannot get ideal results; enhanced safety precautions are required
  Insect cells            Moderately rapid expression; support most protein folding and eukaryotic-type PTM of the expression protein; works well for non-enveloped and enveloped VLPs, free of mammalian pathogens   High cost; difficult to scale-up; incomplete modification of proteins; low-level expression, contamination of product with enveloped baculovirus particles; perform simpler *N*-glycosylation compared to mammalian cells
  Mammalian cells         Perform appropriate complex mammalian-type PTMs; perform authentic assembly and folding of recombinant proteins; works well for non-enveloped and enveloped VLPs                            High cost; difficult to scale-up; lengthy expression time; low yield; vulnerable to infection with mammalian pathogens
  Plant cells             Rapid expression; highly scalable; less expensive; free of mammalian pathogens; support most protein folding and eukaryotic-type PTM                                                        Low yield; technical and regulatory issues
                                                                                                                                                                                                                      

HCV VLP Vaccines in Pre-Clinical Studies
========================================

HCV-Derived VLPs
----------------

Virus like particles are attractive candidates to elicit NAb responses as they structurally resemble and are much safer than the wild-type virus from which they are derived ([@B52]; [@B91]; [@B84]). In addition to the hepatitis B virus (HBV) and HPV VLP vaccines, the VLP approach has been used to recently develop a chikungunya virus vaccine that was effective in non-human primates ([@B4]). Self-assembled core-E1-E2 HCV-like particles (HCV-LPs) have been reported to generate HCV-VLPs with biophysical, ultrastructural and antigenic properties similar to those of the putative virion ([@B9], [@B10]). These HCV-LPs were generated in Sf9 cells from recombinant baculovirus encoding the HCV core, E1 and E2 proteins. Immunization with these recombinant HCV-LPs revealed that they can induce strong and broad polyclonal cellular and humoral immunity in mice ([@B10]; [@B60]; [@B68]) as well as in chimpanzees (**Table [1](#T1){ref-type="table"}**) ([@B36]). The immunogenicity of HCV-LPs is strongly dependent on particle formation because vaccination with heat-denatured particles resulted in reduced antigen-specific T-cell and antibody responses ([@B60]). It is proposed that HCV-LP have the ability to interact specifically with dendritic cells (DCs) resulting in their activation and efficient antigen presentation, in contrast to denatured HCV-LPs ([@B68]; [@B6]).

Hepatitis C Virus-LPs that were produced in mammalian cells using an adenovirus-based system generated particles which were reported to resemble the native virions morphologically ([@B27]; [@B56]). Vaccination with these adenovirus-derived HCV-LPs in combination with an anionic self-adjuvanting lipopeptide containing the Toll-like receptor (TLR) 2 agonist Pam~2~Cys (E~8~Pam~2~Cys) resulted in significant HCV-LP and E2-specific antibody responses mice ([@B27]). Up to three doses of non-adjuvanted or traditional alum-adjuvanted HCV-LPs were essential to reach similar HCV-LP- and E2-specific antibody titers induced with a single dose of HCV-LP+E~8~Pam~2~Cys. In addition, these antibodies neutralized the binding and uptake of VLPs by human hepatocellular carcinoma (Huh-7) cells and of cell culture derived HCV (HCVcc). Significant numbers of antigen-specific antibody secreting cells were also detected in the spleen of HCV-LP+E~8~Pam~2~Cys vaccinated mice, correlating with the previous results ([@B27]). Moreover, vaccination of human leukocyte antigen (HLA)-A2 transgenic mice with this vaccine generated higher HCV-LP-specific IFN-γ-mediated responses compared to non-adjuvanted HCV-LPs ([@B27]). In a heterologous prime-boost strategy, immunization with recombinant adenoviruses encoding the HCV structural proteins as a final booster, following priming with HCV-LPs, resulted in enhancement of both antibody and T-cell responses ([@B56]). Additionally, the sera from immunized mice reduced the binding of VLPs and the JFH1 strain of HCV to Huh-7 cells demonstrating the presence of NAbs ([@B56]). Even though different studies have provided evidence that HCV-derived VLPs are a promising vaccine strategy, capable of eliciting HCV-specific humoral and cellular immunity, additional studies are required to determine how best to induce highly protective, long-lasting immune responses.

Recombinant HBV-Based VLPs Containing HCV Epitopes
--------------------------------------------------

Hepatitis B virus-derived VLPs have been evaluated as carriers able to present heterologous epitopes ([@B24]), including HCV-derived antigens. In one approach, chimeric VLPs were generated by fusing target antigens to viral capsid proteins (CPs) capable of self-assembling into VLPs (**Table [1](#T1){ref-type="table"}**). The p24/p27 protein of HBV surface antigen (HBsAg-S) has been reported to self-assemble into potent, non-infectious, secreted subviral particles and has been used in commercial vaccines against hepatitis B for over three decades. HBsAg-S particles have been designed as carriers of foreign epitopes inserted at the N-or C-terminus or into the external hydrophilic loop of the HBsAg-S ([@B76]). HCV-specific epitopes derived from the E2 protein hypervariable region 1 (HVR1) were inserted into recombinant HBsAg VLPs which were secreted from transfected mammalian cells ([@B70]; [@B97]). These particles were recognized by human anti-HCV-positive serum containing anti-HVR1-1b antibodies, suggesting the antigenic structure of the HVR1 region expressed on the particles' surface closely resembled the authentic structure ([@B70]). Subsequently specific antibody responses to HVR1 were efficiently induced ([@B70]; [@B97]). Furthermore, vaccination with a cocktail of HBsAg-S VLPs containing epitopes from either HCV-1a or -1b strains induced antibodies against both HVR1 epitopes that resulted in higher titers than those generated by immunization with the individual VLPs, suggesting a synergistic effect ([@B70]).

The insertion of the full-length HCV E1 and E2 envelope proteins into HBsAg VLPs was also shown to result in chimeric HBV-HCV particles similar in size and shape to the wild-type HBsAg subviral particles ([@B76]). Immunization of rabbits with these HBV-HCV VLPs resulted in high titers of cross-NAbs with the ability to neutralize various HCV genotypes ([@B12]). Recently, the immunogenicity of the chimeric HBsAg VLPs expressing E1 and E2 proteins as separate immunogens were compared with HBsAg VLPs bearing an E1E2 heterodimer ([@B13]). The E1- and E2- specific humoral responses induced in animals vaccinated with HBsAg VLPs expressing E1E2 in their heterodimer conformation, were significantly reduced compared to the responses in rabbits immunized with HBsAg VLPs expressing E1 and E2 separately ([@B13]). Additionally, the E1- and E2-specific antibodies showed increased cross-neutralization of various genotypes of heterologous HCV strains. These results confirmed previous observations ([@B45]), that the E1 and E2 heterodimer is less immunogenic, possibly due to the conformational folding of E1 and E2 at the surface of the HBsAg particles contributing to the masking of certain immunodominant epitopes. Furthermore, although the folding of E1--E2 complex on the surface of the HBsAg particles was demonstrated, the structure of the E1E2 dimers on these particles might not be representative of dimers on the surface of native HCV virions. Nonetheless, these particles also generated significant levels of HBs-specific antibodies, further supporting the development of a bivalent HBV-HCV prophylactic vaccine capable of preventing primary infection with either of these two viruses ([@B13]). Administration of chimeric HBsAg-S/HCV VLP demonstrated that mice ([@B71]) and rabbits ([@B14]) with pre-existing anti-HBsAg antibodies successfully generated anti-HCV antibodies, therefore these chimeric particles can be used in populations with pre-existing immunity to HBV as a strategy to induce protective immunity to HCV. The encouraging results obtained so far support the development of HBV-derived VLP vaccines. However, additional studies are needed to assess the immunogenicity of these chimeric HBV/HCV particles in a larger animal model and also to develop means to further increase the broadly neutralizing characteristics of the resultant NAbs.

The HBV core protein (HBc) naturally self assembles into dimers and subsequently into VLPs and has been used as a VLP carrier for over three decades ([@B28]; [@B20]). Insertion of foreign sequences into the HBc gene does not impede particle formation making HBc suitable for the development of a VLP vaccine displaying a foreign antigen ([@B94]; [@B88]). Segments of HCV genes encoding the core (98 aa) or NS3 (155 aa) proteins, containing B- and T-cell epitopes, were fused to the 3′ end of the HBc gene to generate chimeric HBc/HCV VLPs ([@B66]). These two proteins were chosen as immunogens because the induction of broad CD4+ and CD8+ T-cell responses to various HCV proteins, including core and NS3 is typically associated with resolution and control of HCV infection ([@B72]). Administration of the HBc/HCV core particles induced moderately low antibody levels and proliferative responses of T-cell to HCV core epitopes, while vaccination with the HBc/HCV NS3 particles induced significant levels of anti-NS3 antibodies with no proliferative responses to HCV epitopes ([@B66]). However, antibodies to core and NS3 are believed to have no prophylactic value and are generally not considered to be protective in natural HCV infection. Furthermore, variations in the immune responses to the chimeric particles might be caused by alternative presentation of inserted HCV sequences in the context of the chimeric particles ([@B66]). Similarly, chimeric VLPs carrying a virus-neutralizing HBV pre-S1 epitope and a highly conserved N-terminal HCV core epitope at the C terminus of the truncated HBc protein (HBc-pre-S1-HCVcore) have been successfully generated ([@B88]). Vaccination with these particles induced high T cell immunity similar to that induced by the monovalent HBc-HCV core particles, but induced low antibody responses to HCV core epitopes. It was argued that the core epitopes located at the C terminus were not exposed on the surface of the VLP and therefore were not able to induce strong antibody responses ([@B88]). This further highlights the importance of the position of inserted epitopes within HBc in terms of the particle's humoral immunogenicity. Insertion of larger amino acid sequences would be beneficial for the development and production of a multivalent HCV vaccine carrying a larger number of epitopes coupled to one carrier molecule and facilitate proper folding of conformational epitopes which is important for the generation of NAbs. However, inserting larger inserts within the HBc particles might affect the ability of the chimeric particles to drive insert-specific immune responses. Various studies have reported contradictory results regarding the maximum insertion capacity of HBc without affecting immunogenicity to the insert antigen and HBc's ability to successfully form particles. A maximum of 90 aa of human immunodeficiency virus ([@B53]). Gag protein was reported to be tolerated while fusion of 317, 189, or 100 aa of the Gag protein downstream of aa 144 prevented self-assembly of the chimeric HBc particles ([@B93]). [@B101], on the other hand, reported successful formation of HBc particles carrying a 720 aa segment composed of four copies of an 180 aa sequence derived from HCV core protein. However, the immunogenicity of these particles was not assessed in an *in vivo* model.

Recombinant Retrovirus-Based HCV VLPs
-------------------------------------

Complete glycoproteins can also be displayed in their native conformation on the surface of retroviral particles by a process known as pseudotyping. Infectious HCVpp which are engineered by pseudotyping HCV glycoproteins onto murine leukemia virus (MLV)-Gag retroviral core particles have been used to comprehensively study the early events of HCV infection, as well as the role of putative HCV receptors ([@B8]). These particles are also commonly used to detect and measure anti-HCV NAb in HCV patients ([@B7]; [@B33]). HCV-pseudotyped retrovirus-derived VLPs devoid of a genome (HCV-retro VLPs) have been proposed as a vaccine platform. Studies of the molecular structure of these pseudoparticles described HCVpp and HCV-retro VLPs as regular 100 nm spherical structures comprised of the dense retroviral nucleocapsid surrounded by a lipid bilayer ([@B19]; [@B45]). Following priming with HCV-recombinant viral vectors, VLPs pseudotyped with E2 and/or E1 HCV glycoproteins generated significant anti-E2 and/or anti-E1 antibody titers in mice and macaques ([@B45]). This highlighted the difficulty of inducing an anti-E1 antibody response, consistent with the findings that these antibodies are generally detected at low levels in patients ([@B61]; [@B77]). Of the regimens examined, only the VLPs induced significant levels of anti-E1 antibodies, which were generated provided that E1 was dissociated from E2. More importantly, boosting with the retrovirus-derived VLPs in a heterologous prime-boost combination with plasmo-retroVLP raised NAbs against HCV genotype 1a which cross-neutralized five other genotypes/strains (1b, 2a, 2b, 4, and 5) ([@B50]). No challenge experiments were conducted to assess the anti-HCV potency of these HCV-retro VLPs. Overall, retrovirus-derived VLPs pseudotyped with an assortment of virus envelopes, represent a versatile and efficient platform for vaccination not only against HCV but also against major infectious diseases such HIV/AIDS, yellow fever and dengue fever. However, despite these encouraging results, the use of animal retroviral particles has not been validated as a safe or effective preventative vaccine in humans, and scaling up the manufacturing process may present a limiting factor for the development of recombinant retrovirus-based HCV VLP vaccines.

Recombinant Vesicular Stomatitis Virus Vectors Expressing HCV VLPs
------------------------------------------------------------------

Recombinant vesicular stomatitis virus (rVSV) has been shown to be an effective expression vector in a number of different vaccine strategies (**Table [2](#T2){ref-type="table"}**) ([@B87]; [@B55]). There are several advantages of using rVSV encoding foreign viral proteins as a vaccine candidate. The virus has a low seroprevalence in the community and is not pathogenic in humans; the simple genome has only five genes (N, P, M, G, and L) and it does not undergo reassortment or integration ([@B51]; [@B42]; [@B38]). Recombinant VSV has been evaluated as a candidate for HCV vaccination by encoding HCV core, E1 and E2 proteins (rVSV-C/E1/E2) which can self-assemble into HCV VLPs (VSV-HCV-VLPs) in baby hamster kidney fibroblasts (BHK-21 cells) ([@B38]). These VSV-HCV-VLPs showed similar ultrastructural properties to HCV virions ([@B38]). Vaccination with these particles induced core-, E1- and E2-specific cell mediated responses as well as anti-E2 antibody responses ([@B38]). However, it was argued that these particles may represent the endogenous viruses of BHK-21 cells known as intracisternal R-type particles, rather than the complete budded HCV-like particles ([@B18]). Subsequently it was demonstrated that the expression of HCV E1 and E2 by replication-competent and -defective (G-protein-deleted) VSV vectors resulted in correctly folded E1/E2 heterodimers ([@B64]). Nevertheless, this study only assessed the expression of the envelope proteins but did not provide a detailed characterization of the formed VSV-HCV-VLPs. Immunization with rVSVΔG-C/E1/E2 resulted in significant T cell responses to core, E1 and E2, along with anti-core and anti-E2 antibody responses ([@B38]; [@B64]). Neutralizing antibody responses were not assessed. However, immunization with rVSVΔG-C/E1/E2 protected mice against the formation of tumors expressing HCV E2 (CT26-hghE2t) and showed CT26-hghE2t-specific as well as E2-specific T-cell responses. Recombinant VSV expressing HCV structural proteins represent a versatile tool in vaccine development, which cannot only be used as a vector for the production of HCV VLPs in mammalian cells but also as a vaccine candidate itself. The recent effectiveness of an Ebola vaccine candidate rVSV-ZEBOV ([@B79]), comprising a live-attenuated VSV encoding the Ebola virus glycoprotein, in preventing Ebola virus disease in recently diagnosed patients, their contacts and contacts' contacts ([@B37]; [@B48]; [@B49]) provides hope for the development of a VLP-based HCV vaccine using this strategy. However, further studies are required to better characterize and improve the production VSV-HCV-VLPs. The protective immunity generated by rVSVs encoding HCV core, E1 and E2 also needs to be evaluated before these particles can be used as a vaccine against HCV infection.

DNA Vaccines Encoding Recombinant Retrovirus-Based HCV VLPs
-----------------------------------------------------------

DNA plasmids generating recombinant retro-VLPs (plasmo-retroVLPs) ([@B15], [@B16]; [@B32]) represent a HCV genetic vaccine circumventing the *in vitro* production and purification of retro-VLPs. These plasmo-retroVLPs have been engineered to produce *in situ* retroVLPs pseudotyped with E1 and E2 proteins after *in vivo* delivery of the DNA (**Table [2](#T2){ref-type="table"}**). By doing so, this strategy combines the benefits of DNA vaccines such as the ease of development, low-cost large-scale production and stability with the immuno-stimulatory properties of VLPs, while circumventing the *in vitro* production of VLP vaccines. It has been shown that administration of plasmo-retroVLPs result in the induction of significantly higher antigen-specific responses and antiviral immune protection than plasmids that were mutated to prevent plasmo-retroVLP assembly ([@B15], [@B16]). It was also shown in heterologous prime-boost immunization strategies, that HCV-plasmo-retroVLPs were superior immunogens for boosting cellular and humoral immune responses in primed animals than plasmids unable to form E1/E2-pseudotyped retroVLPs ([@B16]; [@B32]). A combination of two plasmo-retroVLPs vaccinations followed by a boost with *ex vivo* produced VLPs was shown to induce HCV-specific cell-mediated response and NAbs ([@B50]). Furthermore, vaccination with a cocktail of plasmo-retroVLPs pseudotyped with E1E2 from HCV genotypes 1a, 1b, 2b, 3a, 4c, and 5, and/or displaying NS3 antigen in CPs resulted in immune responses against the five HCV genotypes ([@B50]). A major advantage of plasmo-retroVLPs is that they can be re-administered for sequential vaccinations without the concern of pre-existing vector- associated immunity ([@B16]). DNA-based vaccines, however, generally induce relatively weak immune responses to antigens and are therefore regarded as inferior compared to traditional vaccines such as subunit vaccines. As such, even the above strategy required boost immunizations with purified VLPs for maximum activity. The delivery route and/or method of DNA-based vaccines is also a critical factor in determining vaccination outcome. VSV-G specific plasmo-retroVLPs have been shown to induce higher levels of VSV-G-specific humoral and cell mediated immune responses following administration by needle-free intradermal (i.d.) injection compared to immunization with a gene gun ([@B16]). Additionally, needle-free i.d. co-injection of cytokine genes or CpG sequences significantly increased VSV-G-specific NAbs levels ([@B16]). Therefore, attempts should be directed toward the optimization of the delivery methods of DNA-based VLP vaccines and the addition or co-delivery of novel genetic adjuvants for maximum immune stimulation. Together, these results show that the plasmo-retroVLPs is a flexible platform to induce humoral and cellular immunity after homologous or heterologous prime-boost immunization and with further improvements, this strategy could be used as a promising approach to generate enhanced immune responses against HCV.

Recombinant Papaya Mosaic Virus-Based HCV VLPs
----------------------------------------------

Virus like particles derived from plant viruses have also emerged as a promising strategy for the development of viral vaccines. The papaya mosaic virus (PapMV) CP has triggered much interest as an epitope presentation system. Several hundred units of the PapMV CP have been reported to assemble in an organized and repetitive manner into particles ranging from 60 to 100 nm in length following expression in *Escherichia coli* ([@B92]). A recombinant multimeric PapMV vaccine platform expressing a HCV-E2 peptide fused to the C-terminal PapMV CP was shown to trigger a strong humoral immune response in mice lasting more than 120 days against the CP and the E2 epitope (**Table [1](#T1){ref-type="table"}**) ([@B31]). Notably, the same platform was less effective when inoculated as a monomeric protein, confirming the observation that immunogenicity is strongly dependent on the repetitive organization of the antigen ([@B31]). This VLP platform faces challenges which might limit its clinical development as vaccine, including the presence of bacterial RNA used a scaffold for PapMV CP self-assembly ([@B92]), as well as the possibility that antigen fusion might alter the antigen conformation or interfere with the protein assembly and VLP formation.

HCV VLP Production Systems
==========================

Many expression systems for the production of VLPs are currently in use, including various species of yeast such as *Saccharomyces cerevisiae* (*S. cerevisiae*) and *Pichia pastoris* (*P. pastoris*), bacteria (mainly *E. coli*), the baculovirus expression vector/insect cell system (BEVS/IC), and various mammalian cell lines, as well as various plants (tobacco, lettuce leaves) (**Table [3](#T3){ref-type="table"}**). The production system used depends on the need to retain more consistent original VLP formation and post translational modifications (PTMs, e.g., glycosylation and phosphorylation) while significantly reducing production times and costs. All production systems have advantages and drawbacks as discussed briefly.

Bacteria and Yeast
------------------

Bacterial systems are the most commonly used system to manufacture recombinant proteins and have been used to produce non-enveloped HCV VLPs. *E. coli*-derived HCV core proteins self-assembled *in vitro* into particles of approximately 60 nm in diameter ([@B57]). [@B63] on the other hand, produced VLPs in *E. coli* following expression of truncated HCV core protein consisting of the first 120 amino acids. Similarly, the recombinant HCV-E2 PapMV CP VLPs were also produced following expression in *E. coli* ([@B31]; [@B80]). However, several factors including the lack of a mammalian-like PTM system means that this platform is not preferred for VLP production (**Table [3](#T3){ref-type="table"}**). Additionally, the downstream processing of the VLPs is compromised by the presence host cell derived toxins, heat shock proteins or chaperone proteins, increasing the final production cost ([@B105]; [@B59]).

Yeast is another well-established platform used for recombinant protein expression and VLP production. Four licensed VLP-based vaccines, Engerix-B^®^, Hepavax-Gene^®^, Recombivax HB^®^ and Gardasil^®^ (Merck and Co), are manufactured using this system. The entire HCV core protein expressed in methylotrophic *P. pastoris* formed particles with similar structural properties as the native mature HCV nucleocapsid particles, and were successfully recognized by serum from a persistently infected HCV patient ([@B1], [@B2]). More recently, VLPs of 70 nm in diameter were generated following expression of recombinant HCV coreE1E2 proteins in *P. pastoris* and were able to efficiently induce anti-CoreE1E2 antibodies in rabbits ([@B41]). However, concerns about appropriate protein processing, protein folding, and post translational modification, may direct the choice toward an alternative production system ([@B2]; [@B58]).

Mammalian Cells
---------------

Mammalian cell expression systems are favored because they are capable of performing appropriate complex mammalian-type PTMs and authentic assembly of recombinant proteins ([@B27]; [@B35]; [@B56]). Various HCV VLPs vaccine candidates have been successfully produced in mammalian cells including Chinese hamster ovary (CHO), Huh-7cells, and human embryonic kidney (HEK) 293T cells (**Table [1](#T1){ref-type="table"}**). Immunization with recombinant HCV envelope glycoproteins produced in mammalian cells protected chimpanzees more effectively compared to those produced in yeast or insect cells after challenge with a homologous HCV isolate ([@B26]). Similarly, mammalian cell-derived recombinant envelope proteins have been reported to bind strongly to human cells compared to those produced in yeast or insect cells ([@B81]). More recently VLPs produced in mammalian cells were found to be more immunogenic in a VLP prime/Rec-Ad-C-E1-E2 boost based heterologous strategy, when compared to VLPs produced using the baculovirus-insect cell system ([@B56]). To avoid the deleterious effects of cesium chloride (CsCl), the use of iodixanol ultracentrifugation and stirred cell ultrafiltration resulted in the production of large quantities of HCV VLPs from various genotypes as a strategy for the manufacture of a quadrivalent mammalian cell derived HCV VLP vaccine ([@B34],[@B35]).

Plant Cells
-----------

Plant production platforms have many advantages compared to mammalian cells (**Table [3](#T3){ref-type="table"}**). Plant-derived VLPs offer a new approach for oral delivery of vaccines. Plant expression systems are highly scalable, economical and free of mammalian pathogens. Additionally, plant production systems possess eukaryotic-like protein folding and PTMs similar to mammalian cells ([@B65]; [@B104]; [@B58]). Plant expression systems are suitable for the production of both non-enveloped and enveloped VLPs ([@B30]; [@B86]). A tobacco mosaic virus (TMV)-derived vector encoding a HVR1peptide (containing a HCV neutralizing epitope) fused to the C-terminus of the B subunit of cholera toxin (CTB) was used to infect tobacco plants (*Nicotiana benthamiana*) ([@B69]; [@B85]). Infected plants successfully generated TMV particles expressing HVR1/CTB ([@B69]). The plant-derived HVR1/CTB reacted with anti-HRV1 monoclonal antibodies and sera from HCV-positive individuals infected with four of the major genotypes of HCV. Inoculating mice with plant extract resulted in the induction of both anti-CTB and anti-HVR1 antibodies capable of specifically binding to HCV VLPs ([@B69]). A plant-derived HCV vaccine can reduce manufacturing costs associated with the production of conventional vaccines and the vaccine can be administered in edible plant part this would particularly helpful in reducing incidence of HCV in the developing world. However, to date no plant-derived VLPs have been licensed for human use. In addition, the dosage required for effective vaccination might vary depending on the plants used, ripeness of the fruit and the quantity of food consumed. Therefore, administration of edible vaccines requires to be standardized to evaluate the dosage requirement for effective vaccination. Also, certain plants and fruits are generally not eaten raw and cooking would result in denaturation of the protein and a reduction in immunogenicity to the vaccine. Most plants and fruits are susceptible to microbial infestation and this would affect the stability of the vaccine.

Insect Cells
------------

The baculovirus-insect cell expression system has also been widely used for VLP production ([@B95]). Insect cells have been employed to express several VLP-based vaccines, notably one of the current HPV vaccines, Cervarix^®^. The baculovirus--insect cell system can be used to manufacture non-enveloped and enveloped VLPs (**Table [3](#T3){ref-type="table"}**) and various HCV VLPs have been successfully produced using this system (**Table [1](#T1){ref-type="table"}**) ([@B10]; [@B99]; [@B25]; [@B106]). The insect cell system can perform eukaryotic-type PTMs, support high expression levels of foreign proteins with the advantage of lacking mammalian pathogens ([@B83]; [@B58]). Expression of core, E1 and E2 proteins in the recombinant baculovirus system resulted in the formation of recombinant virus particles ([@B9], [@B10], [@B11]) capable of inducing antibodies and cell-mediated immune responses after immunization in rabbits. A major disadvantage of this system is contamination of the product with co-produced enveloped baculovirus particles ([@B22]; [@B75]), which require the development of more complex and stringent VLP purification systems. Another limitation of this system is that insect cells perform simpler *N*-glycosylation compared to mammalian cells, which is troublesome in vaccine developments as correct glycosylation is often necessary for optimum immunogenicity of the vaccine antigen ([@B54]; [@B73]).

Downstream Processing of VLP Vaccines
=====================================

The purity, potency and consistency of the particles and elimination of host cell and culture media contaminants are crucial for the downstream processing of VLP-based vaccines. In addition, the purification methods should be robust, cost-effective, scalable and preferably applicable to a wide variety of VLPs.

Virus like particles are purified using methods originally developed for the purification of viruses by which particles are purified based on their size and density using ultracentrifugation through sucrose or CsCl gradients ([@B96]). However, ultracentrifugation-based methods are not practical for large scale vaccine development as they are non-scalable, tedious and highly labor intensive. Furthermore, use of CsCl is problematic due to its toxicity, reduced infectivity of viruses and particle deformation ([@B23]). Due to these limitations, there is currently a trend moving away from traditional VLP purification methods toward more scalable sophisticated techniques such as chromatography ([@B67]; [@B96]). Here, crude lysate is initially clarified by low-speed centrifugation or tangential flow filtration prior to chromatography (ion exchange, affinity, or size-exclusion). Chromatography provides a convenient and practical intermediate step for capturing and concentrating VLPs from cellular and media contaminants ([@B67]).

Conclusion
==========

The path to a HCV vaccine has been fraught with difficulties mainly because of the virulent nature of the virus and its ability to evade the immune responses due to its heterogeneity. However, advances in technology and our understanding of the natural course of HCV infection, the pathogenetic mechanisms, and the immunological markers which correlate with resolution of infection or protection, provide useful information for vaccine design. VLP vaccines have many favorable immunological characteristics making them promising HCV vaccine candidates. Currently, no VLP-based HCV vaccines have progressed to human clinical trials. However, VLP-based vaccines for the prevention of HBV and HPV infections have already been licensed, supporting the development of VLP-based vaccines for HCV. The HCV VLP-based vaccine candidates that have been developed so far have generated promising data in pre-clinical animal studies. It is widely known that several factors, including the expression system, will affect the quality and production yields of viral particles. Several expression systems have been effectively used to produce VLP vaccine candidate. Some VLP-based HCV vaccine candidates such as chimeric HBV/HCV VLPs can be produced using already established production systems such as bacterial and yeast. However, these particles can be contaminated with residual host cell factors such as lipids, nucleic acids and proteins that may stimulate innate immune responses and/or reduce the specific adaptive immune response and therefore may have a significant impact on VLP-based vaccine development that could present a bottleneck in their development. VLPs produced using mammalian cells offer an alternative system which supports appropriate complex mammalian-type PTMs and performs authentic assembly and folding of recombinant proteins and therefore generates VLPs that are very similar to the authentic HCV virion. However, difficulties in scaling up this system and high-production costs might direct the choice toward more cost effective alternative production system. Genetic vaccines that express HCV-recombinant VLPs, on the other hand are attractive candidates as the production of high quality plasmid DNA is simple and inexpensive to scale-up and could further advance the development of novel VLP-based strategies. Ultimately, it is hoped that newly developed VLPs can elicit specific and strong responses to HCV to prevent and contain infection. These encouraging results from pre-clinical animal studies suggest that it should be possible to develop such a vaccine although this may yet be some way off.
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